BIDEN’S NUCLEAR WAR: US Buys $290 Million Worth of Drugs in Preparation for Nuclear Bomb

Here is yet another cataclysmic news story the Democrat party of war and their media ministry if war propaganda are censoring.The party of war is preparing for nuclear catastrophe all by their own design.

Watch this NYC public service announcement:

Story continues below advertisement

US Buys $290 Million Worth of Drugs in Preparation for Nuclear Emergencies

By Mimi Nguyen Ly, The Epoch Times, October 6, 2022 Updated: October 6, 2022

The U.S. Department of Health and Human Services (HHS) is buying $290 million worth of drugs as part of its “long-standing, ongoing efforts to be better prepared to save lives following radiological and nuclear emergencies.”

HHS is purchasing a supply of the drug Nplate from Amgen USA, a biotechnology headquartered in Thousand Oaks, California.

The $290 million purchase was announced on Oct. 4 by the Administration for Strategic Preparedness and Response (ASPR), an agency within the HHS that’s tasked with preparing the nation for future disasters and public health emergencies.

Nplate is the trade name of romiplostim, which was approved by the U.S. Food and Drug Administration (FDA) in January 2021 to treat blood cell injuries that accompany acute radiation syndrome (ARS) in adults and children.

ARS is also referred to as radiation sickness, which reaches internal organs in mere seconds and “occurs when a person’s entire body is exposed to a high dose of penetrating radiation.” It can result in a difficulty for blood to clot because of low platelet counts, which can lead to uncontrolled bleeding, which is life-threatening.

Nplate helps reduce the radiation-induced bleeding by stimulating the body to produce more platelets.

According to the announcement, Amgen’s development of Nplate for radiation sickness was supported by the Biomedical Advanced Research and Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID). BARDA is part of the HHS ASPR, and NIAID is part of the National Institutes of Health (NIH).

“BARDA is using its authority provided under the 2004 Project Bioshield Act and $290 million in Project BioShield designated funding to purchase this supply of the drug,” the ASPR announcement reads.

The U.S. government launched Project Bioshield in 2004 to incentivize private companies to develop vaccines and other countermeasures to deal with future chemical, biological, radiological, and nuclear threats. It was initially provided with some $5.6 billion to be funded through fiscal year 2013, and later another $2.8 billion to be funded from FY 2014 to FY 2018.

“Amgen will maintain this supply in vendor-managed inventory,” ASPR said of the Nplate drug supply. “This approach decreases life-cycle management costs for taxpayers because doses that near expiration can be rotated into the commercial market for rapid use prior to expiry and new doses can be added to the government supply.”

NIAID announced in February 2021 that the FDA approval of romiplostim or Nplate was a result of its collaboration with BARDA and Amgen.

“The FDA’s decision was based largely on NIAID-supported studies showing that romiplostim greatly increases survival in an animal model of radiation exposure,” NIAID stated at the time.

Nplate is also otherwise FDA-approved for people with immune thrombocytopenia, a blood disorder that results in low platelet counts.

“Repurposing drugs for acute radiation syndrome that also are approved for a commercial indication helps to sustain availability of the product and improves healthcare provider familiarity with the drug,” ASPR announced on Oct. 4.

The Truth Must be Told

Your contribution supports independent journalism

Please take a moment to consider this. Now, more than ever, people are reading Geller Report for news they won't get anywhere else. But advertising revenues have all but disappeared. Google Adsense is the online advertising monopoly and they have banned us. Social media giants like Facebook and Twitter have blocked and shadow-banned our accounts. But we won't put up a paywall. Because never has the free world needed independent journalism more.

Everyone who reads our reporting knows the Geller Report covers the news the media won't. We cannot do our ground-breaking report without your support. We must continue to report on the global jihad and the left's war on freedom. Our readers’ contributions make that possible.

Geller Report's independent, investigative journalism takes a lot of time, money and hard work to produce. But we do it because we believe our work is critical in the fight for freedom and because it is your fight, too.

Please contribute here.

or

Make a monthly commitment to support The Geller Report – choose the option that suits you best.

Quick note: We cannot do this without your support. Fact. Our work is made possible by you and only you. We receive no grants, government handouts, or major funding. Tech giants are shutting us down. You know this. Twitter, LinkedIn, Google Adsense, Pinterest permanently banned us. Facebook, Google search et al have shadow-banned, suspended and deleted us from your news feeds. They are disappearing us. But we are here.

Subscribe to Geller Report newsletter here— it’s free and it’s essential NOW when informed decision making and opinion is essential to America's survival. Share our posts on your social channels and with your email contacts. Fight the great fight.

Follow Pamela Geller on Gettr. I am there. click here.

Follow Pamela Geller on
Trump's social media platform, Truth Social. It's open and free.

Remember, YOU make the work possible. If you can, please contribute to Geller Report.

Join The Conversation. Leave a Comment.

We have no tolerance for comments containing violence, racism, profanity, vulgarity, doxing, or discourteous behavior. If a comment is spammy or unhelpful, click the - symbol under the comment to let us know. Thank you for partnering with us to maintain fruitful conversation.

If you would like to join the conversation, but don't have an account, you can sign up for one right here.

If you are having problems leaving a comment, it's likely because you are using an ad blocker, something that break ads, of course, but also breaks the comments section of our site. If you are using an ad blocker, and would like to share your thoughts, please disable your ad blocker. We look forward to seeing your comments below.

Sponsored
Geller Report
Thanks for sharing!